Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
Intuitive Surgical, Inc. (ISRG) – Form 144 filing: an unidentified insider has notified the SEC of a planned sale of 5,600 common shares through broker Charles Schwab. The shares were acquired via stock-option exercise on 12-03-2018. Proposed sale date is 28-Jul-2025.
The filing lists an aggregate market value of US$2.77 million, implying a price of roughly US$495 per share. Relative to the company’s 358.48 million shares outstanding, the disposition represents only about 0.0016 %, so it is immaterial to the public float. No prior sales were reported for the past three months and no Rule 10b5-1 trading plan date is supplied.
Form 144 indicates intent rather than completion; actual execution will depend on market conditions and the insider’s discretion. While insider selling can sometimes be viewed cautiously by investors, the small size versus total shares and lack of accompanying negative disclosures suggest limited market impact.
Intuitive Surgical (ISRG) EVP & Chief Medical Officer Myriam Curet filed a Form 4 for transactions dated 07/25/2025.
- Option exercise: 4,500 non-qualified options exercised at $242.3367 under the 2010 Incentive Award Plan.
- Share sale: The 4,500 resulting shares were immediately sold at $492.48, generating gross proceeds of roughly $2.2 million.
- Ownership: After both trades, Curet directly holds 353 common shares; net beneficial ownership is unchanged.
- Derivative position: 5,030 options remain outstanding.
- Transactions were executed under a Rule 10b5-1 trading plan that expires 13 Aug 2025.
The filing is routine, disclosing compliance with Section 16 insider-trading rules and does not alter control or capital structure.